TRADE MARKS ACT 1995
DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS
Re:Opposition by Glaxo Group Limited to registration of trade mark application 1088656(1, 5, 42, 44) - AVEXA - filed in the name of Avexa Limited.
Delegate: Alison Windsor Representation: Opponent: Fiona Symons of Davies Collison Cave, patent and trade mark attorneys
Applicant: Dr Warwick Rothnie of counsel instructed by Ellis Technology LawyersDecision: 2009 ATMO 84
S52 opposition: ss42(b), 44, 59 and 60 – no grounds established - - opposition fails – costs awarded against opponentBackground
Avexa Limited (“the applicant”) filed an application to register a trade mark, current details of which are shown below:
Trade mark number: 1088656
Filing date: 2 December 2005Goods/service specifications: Class 1: Chemicals for use in science, research and industry; chemicals and chemical reagents for use in the manufacture of pharmaceuticals
Class 5:Pharmaceutical preparations and substances including preparations for healthcare, chemicals and chemical preparations and substances used for medicinal and pharmaceutical purposes and in medicines
Class 42:Scientific and technological services and research and design relating thereto; industrial analysis and research services
Class 44:Medical services, healthcare services; advisory services relating to healthcare
Trade Mark: AVEXA
The application was examined as required by section 31 of the Trade Marks Act 1995 (“the Act”) and on 8 March 2007 was advertised in the Australian Official Journal of Trade Marks as accepted for possible registration.
On 11 May 2007 Glaxo Group Limited (“the opponent”) filed a notice of opposition (“the notice”) in the broadest possible terms. Evidence in support, in answer and in reply were filed in due course. The opponent then requested a hearing.
I heard the opposition in Melbourne on 24 July 2009 in my capacity as a delegate of the Registrar of Trade Marks. At the hearing, the applicant was represented by Dr Warwick Rothnie of counsel, instructed by Ellis Technology Lawyers. The opponent was represented by Fiona Symons of Davies Collison Cave, patent and trade mark attorneys.
Grounds of opposition and onus
At the hearing the opponent pursued only the following grounds:
· Paragraph 42(b) – use contrary to law
· Section 44 – identical etc trade mark, specifically in relation to registration no. 1010296 – KIVEXA – for pharmaceutical preparations and substances in class 5
· Section 59 – the applicant does not intend to use or authorise use of the trade mark or assign it to a body corporate
· Section 60 – trade mark similar to one with a reputation within Australia.
As none of the other grounds nominated on the notice were referred to, I find that none of them have been established.
The onus is on the opponent to establish one or more of the four grounds it pursued. The standard to be applied in deciding the matter is that of “the balance of probabilities”.[1] The facts relevant to the opposition are to be judged as at the priority date.
Keep reading for free
Create a free CaseChat account to read Glaxo Group Limited v Avexa Limited [Sec=Unclassified] and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2009] ATMO 84
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the Hearing Officer was whether the opponent had established a prima facie case that the applicant lacked the requisite intention to use the trade mark "AVEXA" in relation to Class 5 goods at the time of filing the application. The opponent also raised issues under sections 44, 42, and 60 of the Act, but the Hearing Officer indicated that the determination of the section 59 ground would likely impact the consideration of these other grounds.
The Hearing Officer considered evidence from the opponent suggesting that at the time of filing, the applicant's direction had not been fully scoped and that the mark "AVEXA" would not be the name of a new product, nor would it be used for future pharmaceutical products. The opponent also pointed to the applicant's failure to apply for TGA listing for the name and its lack of evidence of use. However, the Hearing Officer found that the opponent had not established any ground of opposition. The Hearing Officer specifically noted that the existence of a previously registered trade mark, which the opponent had not opposed, was not taken into account in the decision.
The opposition was dismissed, and the application for the trade mark "AVEXA" was permitted to proceed to registration one month from the date of the decision, subject to any notification of an appeal. Costs were awarded against the opponent.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi